Livzon Pharma Reports No Share Capital Changes in October; Confirms Public Float Compliance

Bulletin Express11-02

Livzon Pharmaceutical Group Inc. released its Monthly Return for Equity Issuer for the period ended 31 October 2026, showing stable share capital across both its Hong Kong–listed H shares and Shenzhen-listed A shares.

Total authorised share capital stood at 887.91 million shares, split between 299.81 million H shares and 588.10 million A shares, each with a par value of RMB 1.00. The figures were unchanged from the prior month.

Issued share volumes also remained flat. H shares in issue totalled 299.81 million, while A shares totalled 588.10 million; the company held no treasury shares in either class. Livzon Pharma confirmed that its H-share public float continues to meet the Hong Kong Stock Exchange’s 5 percent minimum requirement for PRC issuers with other listed shares.

The filing noted no activity in share options, warrants, convertible securities, or other equity instruments during the month. All statutory and regulatory obligations associated with the company’s share capital were declared satisfied by the company secretary, Liu Ning, upon submission of the report on 2 November 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment